drugset / Trial / NCT01789320

Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

NCT01789320

Phase 1/2 Completed 11 enrolled Clearside Biomedical, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.

Timeline

Start
2013-02
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Triamcinolone Acetonide Other / unclassified 4 mg Other